News Summary

A federal jury in California has ruled that Apple must pay $634 million to Masimo, a medical technology company, for infringing on patents related to blood-oxygen monitoring technology used in the Apple Watch. The case is part of a larger legal battle between the two companies, with Masimo accusing Apple of infringing on its pulse oximeter patents. Apple has expressed its disagreement with the verdict and plans to appeal, noting that the single patent in question expired in 2022 and pertains to outdated patient monitoring technology. Despite the ruling, Apple had previously redesigned its blood-oxygen monitoring feature, which was approved by the US Customs and Border Protection, although Masimo has filed a lawsuit against the agency for permitting the sale of these updated Apple Watches without its consultation.